Dutch biotech uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile, tolerability and sustained ...
In 1872, a young American doctor named Dr. George Huntington published a paper titled “On Chorea,” where he described an ...
Huntington's chorea, formerly known as "St. Vitus' dance," is a rare and incurable brain disorder characterized by movement ...
Huntington's disease, formerly known as "St. Vitus' dance," is a rare and incurable brain disorder characterized by movement ...
Doctors have reported the first successful treatment for Huntington’s disease, describing the breakthrough as a major step ...
I cried with every single patient,” Sung says. “It just was this crazy feeling that, for the patients and families, almost can’t feel real.” The treatment, known as AMT-130, is delivered deep into the ...
After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...
Stunning success in halting Huntington's disease with gene therapy offers new hope to those with the disorder—and potential ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
An experimental gene therapy was found to slow the progression of Huntington's disease in a "pivotal" Phase 1/2 study, according to drugmaker uniQure, marking a major step toward a potential first ...
SAN FRANCISCO--(BUSINESS WIRE)--Helping a loved one manage their money is one of the most common and overlooked financial challenges in banking today. More than 100 million Americans help an aging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback